Suppressive effects of nitric oxide-releasing prednisolone NCX-1015 on the allergic pleural eosinophil recruitment in rats

Clinical and Experimental Allergy

Volumn 38, Issue 11, 2008, Pages 1830-1837

  Oliveira, M S S ^a   Barreto, E D O ^a   Zamuner, S ^b   Pires, A L A ^a   Ferreira, T P T ^a   Cordeiro, R S B ^a   Lagente, V ^c   Martins, M A ^a   Wallace, J L ^b   E Silva, P M R ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Allergy; Eosinophils; NO steroids

Indexed keywords

ALUMINUM HYDROXIDE; ARACHIDONATE 5 LIPOXYGENASE; DIETHYLENETRIAMINE NONOATE; EOTAXIN; MIFEPRISTONE; NCX 1015; NITRIC OXIDE DONOR; OVALBUMIN; PEPTIDOLEUKOTRIENE; PREDNISOLONE; PREDNISOLONE 21 [4' (NITROOXYMETHYL)BENZOATE]; PREDNISOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; EXPERIMENTAL MODEL; LOEFFLER PNEUMONIA; MALE; MONOTHERAPY; NONHUMAN; PLEURA FLUID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSITIZATION; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; CHEMOKINE CCL11; CYSTEINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; EOSINOPHILIA; EOSINOPHILS; HYPERSENSITIVITY; LEUKOCYTES; LEUKOCYTES, MONONUCLEAR; LEUKOTRIENES; MALE; MIFEPRISTONE; NEUTROPHILS; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; OVALBUMIN; PLEURAL CAVITY; PLEURISY; PREDNISOLONE; RATS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID;

EID: 54849436872     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.03083.x     Document Type: Article

References (32)

1. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006 148 : 245 54.
2. Gardai SJ, Hoontrakoon R, Goddard CD et al. Oxidant-mediated mitochondrial injury in eosinophil apoptosis: enhancement by glucocorticoids and inhibition by granulocyte-macrophage colony-stimulating factor. J Immunol 2003 170 : 556 66.
3. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998 94 : 557 72.
4. Schacke HDW, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002 96 : 23 43.
5. Belvisi MG, Wicks SL, Battram CH et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 2001 166 : 1975 82.
6. Song IH, Gold R, Straub RH, Burmester GR, Buttgereit F. New glucocorticoids on the horizon: repress, don't activate!. J Rheumatol 2005 32 : 1199 207.
7. Burgaud JL, Ongini E, Del Soldato P. Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann N Y Acad Sci 2002 962 : 360 71.
8. Wallace JL, Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 2003 17 : 11 20.
9. Paul-Clark M, Del Soldato P, Fiorucci S, Flower RJ, Perretti M. 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br J Pharmacol 2000 131 : 1345 54.
10. Hyun E, Bolla M, Steinhoff M, Wallace JL, Soldato PD, Vergnolle N. Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol 2004 143 : 618 25.
11. Wallace JL, Rizzo G, Cirino G, Del Soldato P, Fiorucci S. Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-kappaB. J Pharmacol Exp Ther 2004 310 : 1096 102.
12. Paul-Clark MJ, Mancini L, Del Soldato P, Flower RJ, Perretti M. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci U S A 2002 99 : 1677 82.
13. Turesin F, del Soldato P, Wallace JL. Enhanced anti-inflammatory potency of a nitric oxide-releasing prednisolone derivative in the rat. Br J Pharmacol 2003 139 : 966 72.
14. Keefer LK, Nims RW, Davies KM, Wink DA. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol 1996 268 : 281 93.
15. Silva PM, Alves AC, Serra MF et al. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme. Br J Pharmacol 2001 134 : 283 94.
16. Lima MC, Martins MA, Perez SA, Peixoto JM, Silva PM, Cordeiro RS. Kinetics of pleural exudation and cellular alterations induced by antigen in actively sensitized rats. Braz J Med Biol Res 1990 23 : 857 60.
17. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10 year follow-up on the PAT study. Allergy 2007 62 : 943 8.
18. Lee YC, Lee KS, Park SJ et al. Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid. FASEB J 2004 18 : 1917 9.
19. Rothenberg ME. Eosinophils in the new millennium. J Allergy Clin Immunol 2007 119 : 1321 2.
20. Bandeira-Melo C, Bonavita AG, Diaz BL et al. A novel effect for annexin 1 derived peptide ac2-26: reduction of allergic inflammation in the rat. J Pharmacol Exp Ther 2005 313 : 1416 22 Epub 22 March 2005].
21. e Silva PM, Martins MA, Lima MC, Alves AC, Diaz BL, Cordeiro RS. Pharmacological modulation of the late eosinophilia induced by antigen in actively sensitized rats. Int Arch Allergy Immunol 1992 98 : 355 60.
22. Neves JS, Lima LM, Fraga CA et al. Evaluating the prophylactic potential of the phtalimide derivative LASSBio 552 on allergen-evoked inflammation in rats. Eur J Pharmacol 2005 511 : 219 27.
23. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003 111 : S18 34 discussion S34-16.
24. Paul-Clark MJ, Roviezzo F, Flower RJ et al. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol 2003 171 : 3245 52.
25. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991 43 : 109 42.
26. Muijsers RB, Folkerts G, Henricks PA, Sadeghi-Hashjin G, Nijkamp FP. Peroxynitrite: a two-faced metabolite of nitric oxide. Life Sci 1997 60 : 1833 45.
27. Kenyon NJ, van der Vliet A, Schock BC, Okamoto T, McGrew GM, Last JA. Susceptibility to ozone-induced acute lung injury in iNOS-deficient mice. Am J Physiol Lung Cell Mol Physiol 2002 282 : L540 5.
28. Paul-Clark M, Mancini L, Del Soldato P, Flower RJ, Perretti M. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci U S A 2002 99 : 1677 82.
29. Katsuyama K, Shichiri M, Marumo F, Hirata Y. NO inhibits cytokine-induced iNOS expression, NF-kappaB activation by interfering with phosphorylation and degradation of IkappaB-alpha. Arterioscler Thromb Vasc Biol 1998 18 : 1796 802.
30. Conran N, Ferreira HH, Lorand-Metze I, Thomazzi SM, Antunes E, de Nucci G. Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface. Br J Pharmacol 2001 134 : 632 8.
31. Beauvais F, Joly F. Effects of nitric oxide on the eosinophil survival in vitro. A role for nitrosyl-heme. FEBS Lett 1999 443 : 37 40.
32. Di Filippo C, Rossi F, Ongini E, Del Soldato P, Perretti M, D'Amico M. The distinct alterations produced in cardiovascular functions by prednisolone and nitro-prednisolone (NCX-1015) in the rat highlight a causal role for endothelin-1. J Pharmacol Exp Ther 2004 310 : 1133 41.